Objective
Diabetes is one of the most prevalent global non-communicable diseases, affecting 60 million people in Europe, 10% of whom with type 1 diabetes. Normalising elevated glucose levels decreases symptoms, prevents microvascular complications, improves cardiovascular health and saves lives, but creates a significant risk for hypoglycaemia when insulin treatment is required. Hypoglycaemia is a serious event associated with cognitive decline, reduced quality of life, cardiovascular events and mortality. Hypoglycaemia remains the principal barrier to achieve glucose levels necessary to prevent diabetic complications of chronic hyperglycaemia.
The overall objective of Hypo-RESOLVE is to alleviate the burden and consequences of hypoglycaemia, to be achieved by answering several key questions through a unique public-private partnership. Hypo-RESOLVE will construct secure sustainable databases with data from 100-150 clinical trials offering huge statistical power to establish the glucose threshold(s) below which hypoglycaemia constitutes a risk for poor outcomes in various populations. This will provide valuable input for an evidence based classification of hypoglycaemia to be adopted by regulators, patient organisations and other stakeholders, for application in future trials, the clinic and epidemiologic studies. The basic science and translational research line of Hypo-RESOLVE will advance our understanding on mechanisms underlying consequences of hypoglycaemia and explore novel pathways for the restoration of impaired awareness of hypoglycaemia. Finally, we will determine the significance of CGM-detected low glucose and investigate psychological and economic impacts of hypoglycaemia to quantify the burden of hypoglycaemia both for the individual and next-of-kin, as well as for society.
Altogether, Hypo-RESOLVE will importantly further our knowledge of hypoglycaemia, (facilitate to) reduce its burden and contribute to a better life for patients with insulin-treated diabetes
Fields of science
Not validated
Not validated
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
6525 GA Nijmegen
Netherlands
See on map
Participants (26)
WC2R 2LS London
See on map
8010 Graz
See on map
CB2 1TN Cambridge
See on map
34000 Montpellier
See on map
5230 Odense M
See on map
Participation ended
1015 LAUSANNE
See on map
S10 2TN Sheffield
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
S10 2SB Sheffield
See on map
3400 Hillerod
See on map
DD1 4HN Dundee
See on map
66386 St Ingbert
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1206 Geneve
See on map
35122 Padova
See on map
EH8 9YL Edinburgh
See on map
2880 Bagsvaerd
See on map
RG21 4FA Basingstoke
See on map
Participation ended
65929 Frankfurt Am Main
See on map
94502 Alameda
See on map
1131 Tolochenaz
See on map
10281 NEW YORK
See on map
1170 Bruxelles / Brussel
See on map
02111 Boston
See on map
10169 New York
See on map
Participation ended
6525 XZ Nijmegen
See on map
LE1 7RH Leicester
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
LE1 5WW Leicester
See on map